GEMS22: The Genetic Epidemiology of Metabolic Syndrome (GEMS) study consists of dyslipidaemic cases (age 20–65 years) matched with normolipidaemic controls by sex and recruitment site, drawn from non-Mediterranean subjects of the Genetic Epidemiology of Metabolic Syndrome study (Finland, Switzerland, Canada, Australia, USA).
